BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Figure 4 BIRC3 promotes the resistance of human epidermal growth factor receptor 2-position gastric cancer to trastuzumab by promote the proliferation of tumor cell. A: BIRC3 was depleted using BIRC3-siRNA in NCI-N87R cells. Cell viabilities of N87R-siRNA cells and N87R-siNC 1000 μg/mL trastuzumab were examined by cell counting kit-8 assay; B: mRNA levels of BIRC3 in N87 cells after transfection of BIRC3 overexpressing plasmids or control empty plasmids (designated as N87-BIRC3-OE and N87-BIRC3-NC) were examined by reverse transcription polymerase chain reaction; C: Protein levels of BIRC3 in N87-BIRC3-OE and N87-BIRC3-NC were examined by western blotting. β-actin was a negative control; D: Cell viabilities of N87-BIRC3-OE and N87-BIRC3-NC cells 1000 μg/mL trastuzumab were examined by cell counting kit-8 assay; E: Cell viabilities of N87-BIRC3-OE and N87-BIRC3-NC cells 1000 μg/mL trastuzumab were examined by 5-ethynyl-2’-deoxyuridine assay. Tra: Trastuzumab; EdU: 5-ethynyl-2’-deoxyuridine.